CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
New CAR T-cell therapies show promise for pediatric brain tumors
This narrative review synthesizes 18 studies, including preclinical and early-phase clinical trials, regarding CAR T-cell therapy for pediat…
CAR T-cell therapy is showing potential to shrink tumors and extend life in children with aggressive brain cancers like DIPG.
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Nanomedicine delivery systems may enhance immunotherapy efficacy in colorectal cancer
Nanomedicine may boost immunotherapy for colorectal cancer
This systematic review explores how nanomedicine delivery systems (liposomes, polymeric nanoparticles, metal nanoparticles) can remodel the …
Tiny particles could help immune therapies work better against colorectal cancer by changing the tumor environment.
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
New CD38 CAR-T therapy shows high success rates for late-stage multiple myeloma patients
This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in patients with relapsed refractory multiple myeloma.
A new immune therapy targeting CD38 and BCMA offers deep remission for late-stage multiple myeloma patients while managing side effects like…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
CAR T-cell therapy linked to endocrine adverse events in FAERS analysis
CAR T-cell therapy may trigger rare but serious hormone problems like adrenal failure
A retrospective disproportionality analysis and literature review of 269 endocrine adverse event reports from the FAERS database (2017 to Q2…
CAR T-cell therapy can trigger rare but serious hormone problems like adrenal failure, and death risk rises when these issues occur with sev…
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…